Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 SEK | -.--% | +4.99% | -9.98% |
Feb. 06 | Transcript : Boule Diagnostics AB, 2023 Earnings Call, Feb 06, 2024 | |
Feb. 06 | Transcript : Boule Diagnostics AB, 2023 Earnings Call, Feb 06, 2024 |
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.98% | 35.71M | B- | ||
+8.33% | 217B | B | ||
+6.72% | 183B | B- | ||
+10.18% | 131B | B- | ||
+24.91% | 106B | A- | ||
-0.95% | 62.16B | A- | ||
+10.56% | 51.02B | B+ | ||
+4.81% | 50.89B | B+ | ||
-0.24% | 40.16B | A | ||
+1.22% | 34.79B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BOUL Stock
- Ratings Boule Diagnostics AB